| Field | Row 1 |
|---|---|
| adsh | 0000950170-25-072709 |
| cik | 1107421 |
| name | ALAUNOS THERAPEUTICS, INC. |
| sic | 2834 |
| countryba | US |
| stprba | TX |
| cityba | HOUSTON |
| zipba | 77005 |
| bas1 | 2617 BISSONNET ST |
| bas2 | SUITE 233 |
| baph | (346) 355-4099 |
| countryma | US |
| stprma | TX |
| cityma | HOUSTON |
| zipma | 77005 |
| mas1 | 2617 BISSONNET ST |
| mas2 | SUITE 233 |
| countryinc | US |
| stprinc | DE |
| ein | 841475642 |
| former | ZIOPHARM ONCOLOGY INC |
| changed | 20050919 |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250515 |
| accepted | 2025-05-15 16:27:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | tcrt-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-072709 | 20241231 | Liabilities And Stockholders Equity | 2755000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Net Income Loss | -1682000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Accounts Payable Current | 831000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Assets | 2120000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 4145000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Earnings Per Share Basic | -1.0500 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Earnings Per Share Diluted | -0.6700 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Increase Decrease In Receivables | -3000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Operating Expenses | 1743000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Research And Development Expense | 126000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Shares Outstanding | 1601252.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-072709 | 20231231 | Stockholders Equity | -915767000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-072709 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 1601252.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-072709 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 68000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Accounts Payable Current | 516000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 172000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Increase Decrease In Receivables | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Liabilities Current | 1062000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Operating Income Loss | -1092000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Retained Earnings Accumulated Deficit | -920446000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20231231 | Shares Outstanding | 1601252.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-072709 | 20231231 | Stockholders Equity | 922072000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital Common Stock; | ||
| 0000950170-25-072709 | 20240331 | Stockholders Equity | 4797000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Stockholders Equity | 2000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-072709 | 20241231 | Stockholders Equity | 2000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-072709 | 20241231 | Accrued Liabilities Current | 176000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 172000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital Common Stock; | ||
| 0000950170-25-072709 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 6062000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -1917000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -772000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Common Stock Shares Issued | 1601252.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Common Stock Value | 2000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Earnings Per Share Basic | -0.6700 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | General And Administrative Expense | 1617000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Increase Decrease In Accrued Liabilities | 55000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -307000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Net Cash Provided By Used In Operating Activities | -772000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Nonoperating Income Expense | 60000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Operating Income Loss | -1742000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Prepaid Expense And Other Assets Current | 1659000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Prepaid Expense And Other Assets Current | 746000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Research And Development Expense | 347000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Collaboration Agreement With Solasia Pharma Kk; | ||
| 0000950170-25-072709 | 20250331 | Stockholders Equity | -921519000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-072709 | 20250331 | Assets Current | 1067000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 68000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital Common Stock; | ||
| 0000950170-25-072709 | 20241231 | Assets | 2755000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Cash And Cash Equivalents At Carrying Value | 1091000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Common Stock Shares Outstanding | 1601252.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Common Stock Shares Outstanding | 1601252.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-072709 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 140000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Liabilities Current | 692000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Prepaid Expense And Other Assets Noncurrent | 1053000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Receivables Net Current | 2000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Retained Earnings Accumulated Deficit | -921519000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Collaboration Agreement With Solasia Pharma Kk; | ||
| 0000950170-25-072709 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Royalty; Type Of Arrangement= Collaboration Agreement With Solasia Pharma Kk; | ||
| 0000950170-25-072709 | 20241231 | Stockholders Equity | 2063000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Stockholders Equity | 922507000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital Common Stock; | ||
| 0000950170-25-072709 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 319000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240731 | Common Stock Shares Authorized | 34666667.0000 | shares | 0 | us-gaap/2024 | Range= Maximum; | ||
| 0000950170-25-072709 | 20250331 | Common Stock Shares Issued | 38269.0000 | shares | 0 | us-gaap/2024 | Subsequent Event Type= Subsequent Event; Title Of Individual= Board Of Directors; | ||
| 0000950170-25-072709 | 20250331 | Common Stock Shares Outstanding | 1601252.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Common Stock Value | 2000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | General And Administrative Expense | 747000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Increase Decrease In Accounts Payable | -19000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Interest Paid Net | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Liabilities | 692000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Nonoperating Income Expense | 19000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Other Nonoperating Income Expense | 19000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Prepaid Expense And Other Assets Noncurrent | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Stockholders Equity | 922244000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital Common Stock; | ||
| 0000950170-25-072709 | 20240331 | Stockholders Equity | -917449000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-072709 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 1601252.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Accrued Liabilities Current | 231000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Additional Paid In Capital Common Stock | 922575000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1091000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-072709 | 20240131 | Common Stock Shares Authorized | 520000000.0000 | shares | 0 | us-gaap/2024 | Range= Maximum; | ||
| 0000950170-25-072709 | 20240131 | Common Stock Shares Authorized | 34666667.0000 | shares | 0 | us-gaap/2024 | Range= Minimum; | ||
| 0000950170-25-072709 | 20240731 | Common Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | Range= Minimum; | ||
| 0000950170-25-072709 | 20241231 | Common Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Net Income Loss | -1073000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Royalty; Type Of Arrangement= Collaboration Agreement With Solasia Pharma Kk; | ||
| 0000950170-25-072709 | 20241231 | Stockholders Equity | -920446000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-072709 | 20250331 | Stockholders Equity | 1058000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Stockholders Equity | 922575000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital Common Stock; | ||
| 0000950170-25-072709 | 20250331 | Stockholders Equity | 2000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-072709 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Common Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Common Stock Value | 111750000.0000 | USD | 0 | us-gaap/2024 | Subsequent Event Type= Subsequent Event; Title Of Individual= Board Of Directors; | ||
| 0000950170-25-072709 | 20240331 | Earnings Per Share Diluted | -1.0500 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Employee Benefits And Share Based Compensation Noncash | 172000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Employee Benefits And Share Based Compensation Noncash | 68000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Interest Paid Net | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Liabilities And Stockholders Equity | 2120000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Net Income Loss | -1073000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-072709 | 20250331 | Operating Expenses | 1094000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Receivables Net Current | 5000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20231231 | Stockholders Equity | 6307000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 1601252.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Additional Paid In Capital Common Stock | 922507000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20241231 | Assets Current | 2755000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Cash And Cash Equivalents At Carrying Value | 319000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Subsequent Event Type= Subsequent Event; Title Of Individual= Board Of Directors; | ||
| 0000950170-25-072709 | 20241231 | Common Stock Shares Issued | 1601252.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Increase Decrease In Accounts Payable | 315000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Increase Decrease In Accrued Liabilities | -697000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20250331 | Liabilities | 1062000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Net Cash Provided By Used In Operating Activities | -1917000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Net Income Loss | -1682000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-072709 | 20240331 | Other Nonoperating Income Expense | 60000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-072709 | 20240331 | Shares Outstanding | 1601252.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-072709 | 20241231 | Shares Outstanding | 1601252.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-072709 | 20231231 | Stockholders Equity | 2000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-072709 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 1601252.0000 | shares | 1 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Increase Decrease In Receivables | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Receivables | The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Receivables Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Receivables, Net, Current | The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Prepaid Expense And Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Noncurrent | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Additional Paid In Capital Common Stock | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Employee Benefits And Share Based Compensation Noncash | us-gaap/2024 | 0 | 0 | monetary | D | D | Employee Benefit and Share-Based Payment Arrangement, Noncash | Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits. |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Interest Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Paid, Excluding Capitalized Interest, Operating Activities | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Shares, Outstanding | Number of shares issued which are neither cancelled nor held in the treasury. | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-072709 | 2 | 7 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-072709 | 2 | 8 | BS | 0 | H | Receivables Net Current | us-gaap/2024 | Receivables | 0 |
| 0000950170-25-072709 | 2 | 9 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets, current | 0 |
| 0000950170-25-072709 | 2 | 10 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0000950170-25-072709 | 2 | 11 | BS | 0 | H | Prepaid Expense And Other Assets Noncurrent | us-gaap/2024 | Prepaid expenses and other current assets, non current | 0 |
| 0000950170-25-072709 | 2 | 12 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0000950170-25-072709 | 2 | 15 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-072709 | 2 | 16 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses | 0 |
| 0000950170-25-072709 | 2 | 17 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0000950170-25-072709 | 2 | 18 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0000950170-25-072709 | 2 | 19 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 5) | 0 |
| 0000950170-25-072709 | 2 | 21 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock $0.001 par value; 5,000,000 shares authorized, 1,601,252 shares issued and outstanding at March 31, 2025 and at December 31, 2024 | 0 |
| 0000950170-25-072709 | 2 | 22 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2024 | Additional paid-in capital | 0 |
| 0000950170-25-072709 | 2 | 23 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0000950170-25-072709 | 2 | 24 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders' equity | 0 |
| 0000950170-25-072709 | 2 | 25 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders' equity | 0 |
| 0000950170-25-072709 | 3 | 1 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value | 0 |
| 0000950170-25-072709 | 3 | 2 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized | 0 |
| 0000950170-25-072709 | 3 | 3 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued | 0 |
| 0000950170-25-072709 | 3 | 4 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding | 0 |
| 0000950170-25-072709 | 4 | 1 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Revenue | 0 |
| 0000950170-25-072709 | 4 | 3 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0000950170-25-072709 | 4 | 4 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0000950170-25-072709 | 4 | 5 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0000950170-25-072709 | 4 | 6 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0000950170-25-072709 | 4 | 8 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other income, net | 0 |
| 0000950170-25-072709 | 4 | 9 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2024 | Other income, net | 0 |
| 0000950170-25-072709 | 4 | 10 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-072709 | 4 | 11 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Earnings per share, Basic | 0 |
| 0000950170-25-072709 | 4 | 12 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Earnings per share, Diluted | 0 |
| 0000950170-25-072709 | 4 | 13 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted average common shares outstanding, basic | 0 |
| 0000950170-25-072709 | 4 | 14 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted average common shares outstanding, diluted | 0 |
| 0000950170-25-072709 | 5 | 8 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance | 0 |
| 0000950170-25-072709 | 5 | 9 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Balance (in shares) | 0 |
| 0000950170-25-072709 | 5 | 10 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation | 0 |
| 0000950170-25-072709 | 5 | 12 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-072709 | 5 | 13 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance | 0 |
| 0000950170-25-072709 | 5 | 14 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Balance (in shares) | 0 |
| 0000950170-25-072709 | 6 | 6 | CF | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-072709 | 6 | 8 | CF | 0 | H | Employee Benefits And Share Based Compensation Noncash | us-gaap/2024 | Stock-based compensation | 0 |
| 0000950170-25-072709 | 6 | 10 | CF | 0 | H | Increase Decrease In Receivables | us-gaap/2024 | Receivables | 1 |
| 0000950170-25-072709 | 6 | 11 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other current assets | 1 |
| 0000950170-25-072709 | 6 | 12 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-072709 | 6 | 13 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued expenses | 0 |
| 0000950170-25-072709 | 6 | 14 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash flows from operating activities | 0 |
| 0000950170-25-072709 | 6 | 15 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net decrease in cash, cash equivalents and restricted cash | 0 |
| 0000950170-25-072709 | 6 | 16 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents and restricted cash, beginning of period | 0 |
| 0000950170-25-072709 | 6 | 17 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents, end of period | 0 |
| 0000950170-25-072709 | 6 | 19 | CF | 0 | H | Interest Paid Net | us-gaap/2024 | Cash paid for interest | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |